FDA Approves Multaq With REMS, Without Mortality Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Sanofi-Aventis’ atrial fibrillation drug Multaq with a Risk Evaluation and Mitigation Strategy to ensure the drug is used only in patients whose hearts have returned to normal rhythm.
You may also be interested in...
Multaq REMS May Be Revamped As Label Adds New Risks
After several years of regulatory struggles Sanofi’s anti-arrhythmic Multaq finally got to market. But results from a new study have drawn attention to safety problems in higher-risk patients and could damage the drug’s commercial opportunity.
NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq
NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.
NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq
NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.